Antares Pharma, Inc. (NASDAQ:ATRS) gapped up prior to trading on Wednesday . The stock had previously closed at $4.01, but opened at $3.96. Antares Pharma shares last traded at $3.94, with a volume of 1,221,773 shares.
Several equities research analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Antares Pharma in a report on Sunday, September 10th. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Antares Pharma in a report on Friday, September 8th. Vetr raised shares of Antares Pharma from a “buy” rating to a “strong-buy” rating and set a $3.42 price objective for the company in a report on Monday, July 24th. Finally, Chardan Capital assumed coverage on shares of Antares Pharma in a report on Friday, June 23rd. They issued a “buy” rating and a $5.00 price objective for the company. Three research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $4.34.
Antares Pharma (NASDAQ:ATRS) last announced its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.03) by $0.01. Antares Pharma had a negative return on equity of 41.37% and a negative net margin of 34.27%. The company had revenue of $13.42 million during the quarter, compared to analyst estimates of $12.99 million.
In related news, Director Leonard S. Jacob sold 230,000 shares of the firm’s stock in a transaction dated Monday, October 9th. The stock was sold at an average price of $4.05, for a total value of $931,500.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Thomas J. Garrity sold 30,000 shares of the firm’s stock in a transaction dated Tuesday, October 3rd. The shares were sold at an average price of $3.50, for a total value of $105,000.00. The disclosure for this sale can be found here. 11.60% of the stock is owned by company insiders.
A number of institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its holdings in Antares Pharma by 10.1% in the second quarter. Vanguard Group Inc. now owns 6,186,232 shares of the specialty pharmaceutical company’s stock valued at $19,920,000 after acquiring an additional 567,144 shares during the last quarter. Rubric Capital Management LP boosted its holdings in Antares Pharma by 34.4% in the second quarter. Rubric Capital Management LP now owns 3,188,600 shares of the specialty pharmaceutical company’s stock valued at $10,267,000 after acquiring an additional 816,630 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in Antares Pharma by 10.3% in the first quarter. Renaissance Technologies LLC now owns 3,152,569 shares of the specialty pharmaceutical company’s stock valued at $8,953,000 after acquiring an additional 293,228 shares during the last quarter. State Street Corp boosted its holdings in Antares Pharma by 2,682.1% in the second quarter. State Street Corp now owns 2,027,650 shares of the specialty pharmaceutical company’s stock valued at $6,530,000 after acquiring an additional 1,954,769 shares during the last quarter. Finally, JW Asset Management LLC boosted its holdings in Antares Pharma by 27.7% in the second quarter. JW Asset Management LLC now owns 1,671,956 shares of the specialty pharmaceutical company’s stock valued at $5,384,000 after acquiring an additional 362,431 shares during the last quarter. Institutional investors and hedge funds own 36.77% of the company’s stock.
WARNING: This report was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/2956535/antares-pharma-inc-atrs-shares-gap-up-to-3-96.html.
About Antares Pharma
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.
Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.